Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psammocarcinoma with an aggressive course

S H Poggi1, R E Bristow, R K Nieberg

  • 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, California 90027, USA. spoggi@ucla.edu

Obstetrics and Gynecology
|October 9, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and dose modification for patients receiving niraparib.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Safety and dose modification for patients receiving niraparib.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Cytoreductive surgery for ovarian cancer: quality assessment.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.

Gynecologic oncology·2016
Same author

Impact of the 2014 FDA Warnings Against Laparoscopic Power Morcellation.

Journal of minimally invasive gynecology·2016
Same author

Short-term morbidity in transdiaphragmatic cardiophrenic lymph node resection for advanced stage gynecologic cancer.

Gynecologic oncology reports·2016
Same journal

The Political Determinants of Obstetric Prescribing.

Obstetrics and gynecology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.

Obstetrics and gynecology·2026
Same journal

Milestones in Motion: Vaginal Birth After Cesarean.

Obstetrics and gynecology·2026
Same journal

Ebola Virus in Pregnancy.

Obstetrics and gynecology·2026
Same journal

A Quality-Improvement Study Evaluating Three Postpartum Prophylactic Oxytocin Rates and Blood Loss After Vaginal Birth.

Obstetrics and gynecology·2026
Same journal

The Effects of Climate Change on Obstetric and Gynecologic Health.

Obstetrics and gynecology·2026
See all related articles

Psammocarcinoma, a rare ovarian cancer variant, can exhibit aggressive behavior, contrary to its typical indolent course. This case highlights the need for optimal debulking and consideration of adjuvant therapy for aggressive psammocarcinoma.

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Surgical Oncology

Background:

  • Psammocarcinoma is an uncommon ovarian serous cystadenocarcinoma subtype.
  • Characterized by extensive psammoma body deposition.
  • Often presumed to follow an indolent clinical course, similar to low malignant potential tumors.

Observation:

  • A 66-year-old woman presented with bilateral ovarian cystadenofibromata and peritoneal nodules.
  • Initial diagnosis of psammocarcinoma with rare foci of borderline serous tumors.
  • Patient did not receive adjuvant therapy due to the presumed benign nature of the disease.

Findings:

  • The patient developed diffuse psammocarcinoma recurrence with small bowel obstruction 18 months post-surgery.
  • This case demonstrates a more aggressive clinical course than previously reported for psammocarcinoma.

Related Experiment Videos

  • Recurrence involved extensive peritoneal carcinomatosis.

    • Implications:

    • Psammocarcinoma may present with aggressive behavior, challenging the notion of its uniformly indolent course.
    • Optimal surgical debulking is crucial for managing psammocarcinoma.
    • Adjuvant therapy may have a role in treating aggressive psammocarcinoma cases.